DE69431046D1 - Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen - Google Patents

Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen

Info

Publication number
DE69431046D1
DE69431046D1 DE69431046T DE69431046T DE69431046D1 DE 69431046 D1 DE69431046 D1 DE 69431046D1 DE 69431046 T DE69431046 T DE 69431046T DE 69431046 T DE69431046 T DE 69431046T DE 69431046 D1 DE69431046 D1 DE 69431046D1
Authority
DE
Germany
Prior art keywords
eye diseases
treatment
gene therapy
recombinant adenovirus
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69431046T
Other languages
English (en)
Other versions
DE69431046T2 (de
Inventor
Pascale Briand
Michel Perricaudet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Aventis Pharma SA
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Aventis Pharma SA filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of DE69431046D1 publication Critical patent/DE69431046D1/de
Publication of DE69431046T2 publication Critical patent/DE69431046T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69431046T 1993-03-03 1994-02-28 Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen Expired - Fee Related DE69431046T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9302438A FR2702152B1 (fr) 1993-03-03 1993-03-03 Virus recombinants et leur utilisation en thérapie génique.
PCT/FR1994/000220 WO1994020146A1 (fr) 1993-03-03 1994-02-28 Adenovirus recombinants et leur utilisation en therapie genique pour le traitement des pathologies oculaires

Publications (2)

Publication Number Publication Date
DE69431046D1 true DE69431046D1 (de) 2002-08-29
DE69431046T2 DE69431046T2 (de) 2003-02-13

Family

ID=9444602

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69431046T Expired - Fee Related DE69431046T2 (de) 1993-03-03 1994-02-28 Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen

Country Status (15)

Country Link
EP (1) EP0687184B1 (de)
JP (1) JP3835809B2 (de)
AT (1) ATE220923T1 (de)
AU (1) AU693782B2 (de)
CA (1) CA2154355A1 (de)
DE (1) DE69431046T2 (de)
DK (1) DK0687184T3 (de)
ES (1) ES2181710T3 (de)
FR (1) FR2702152B1 (de)
HU (1) HU218900B (de)
NO (1) NO319571B1 (de)
NZ (1) NZ262135A (de)
PT (1) PT687184E (de)
WO (1) WO1994020146A1 (de)
ZA (1) ZA941426B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
IL113052A0 (en) * 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
FR2717823B1 (fr) * 1994-03-23 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2726575B1 (fr) * 1994-11-09 1996-12-20 Rhone Poulenc Rorer Sa Virus recombinants, preparation et utilisation en therapie genique
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2718150B1 (fr) 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
US6107027A (en) * 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US6489305B1 (en) 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
WO2001049316A2 (fr) * 1999-12-30 2001-07-12 Aventis Pharma S.A. Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
FR2803207B1 (fr) * 1999-12-30 2004-04-30 Aventis Pharma Sa Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
CN101507822B (zh) 2003-11-24 2012-06-06 坎吉有限公司 皮肤瘢痕形成的减少
BRPI0515264B1 (pt) 2004-09-13 2018-12-18 Genzyme Corp proteína de fusão de acordo com fórmula x-y-z, composição, molécula de ácido nucleico, seus usos e método de multimerização de um polipeptídeo x
LT2601214T (lt) 2010-08-06 2018-02-26 Genzyme Corporation Vegf antagonistų kompozicijos ir jų panaudojimas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE155038T1 (de) * 1988-09-13 1997-07-15 Biosource Tech Inc Zusammensetzung zur behandlung von degenerativen krankheiten des nervensystems
CA2107789A1 (en) * 1991-04-05 1992-10-06 Thomas E. Wagner Retrovirus inhibition with antisense nucleic acids complementary to packaging sequences

Also Published As

Publication number Publication date
EP0687184A1 (de) 1995-12-20
EP0687184B1 (de) 2002-07-24
HU9502573D0 (en) 1995-10-30
CA2154355A1 (fr) 1994-09-15
JP3835809B2 (ja) 2006-10-18
DK0687184T3 (da) 2002-10-28
JPH08509208A (ja) 1996-10-01
FR2702152A1 (fr) 1994-09-09
HU218900B (hu) 2000-12-28
AU693782B2 (en) 1998-07-09
ATE220923T1 (de) 2002-08-15
HUT73215A (en) 1996-06-28
WO1994020146A1 (fr) 1994-09-15
DE69431046T2 (de) 2003-02-13
NO953329L (no) 1995-08-24
FR2702152B1 (fr) 1995-05-24
NZ262135A (en) 2000-12-22
NO953329D0 (no) 1995-08-24
NO319571B1 (no) 2005-08-29
ES2181710T3 (es) 2003-03-01
PT687184E (pt) 2002-12-31
AU6144494A (en) 1994-09-26
ZA941426B (en) 1994-10-04

Similar Documents

Publication Publication Date Title
DE69431046D1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
DE69630890D1 (de) Peptid-immitierende substanzen in der krebstherapie
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
FI955552A0 (fi) Adenoviraalisia eläinperäisiä vektoreita ja niiden käyttö geeniterapiassa
ATE438397T1 (de) Pharmazeutische zubereitung enthaltend pioglitazone und glimepiride zur verwendung in der behandlung von diabetes
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DE3877529D1 (de) Herstellung von hoch-gereingtem menschlichen faktor ix sowie anderem plasmaproteinkonzentrat und dessen therapeutische verwendung.
DE69034018D1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE69629570D1 (de) 3'utr des menschliches prohibitin-gens
ATE382061T1 (de) Mittel zur induktion von apoptosis und zur therapieanwendung
ATA901396A (de) Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten
ATE70181T1 (de) Verwendung von oxochinazolinderivaten bei der behandlung von hyperurikaemie.
ATE206930T1 (de) Verwendung von osteoblast-proliferationsfaktor
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
ATE79759T1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
ATE136776T1 (de) Verwendung von heptastigmin zur behandlung der zerebralen ictus
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
UA29648A (uk) Спосіб лікування хімічних опіків стравоходу
DE69804034D1 (de) Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8339 Ceased/non-payment of the annual fee